Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital Changes
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sunshine Biopharma (SBFM) Beginning Cash Balance: 2010-2025

Historic Beginning Cash Balance for Sunshine Biopharma (SBFM) over the last 12 years, with Sep 2025 value amounting to $10.1 million.

  • Sunshine Biopharma's Beginning Cash Balance fell 17.94% to $10.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.7 million, marking a year-over-year decrease of 38.18%. This contributed to the annual value of $15.2 million for FY2024, which is 31.61% down from last year.
  • As of Q3 2025, Sunshine Biopharma's Beginning Cash Balance stood at $10.1 million, which was up 19.11% from $8.5 million recorded in Q2 2025.
  • Over the past 5 years, Sunshine Biopharma's Beginning Cash Balance peaked at $41.7 million during Q3 2022, and registered a low of $991,951 during Q1 2021.
  • For the 3-year period, Sunshine Biopharma's Beginning Cash Balance averaged around $15.0 million, with its median value being $15.9 million (2024).
  • In the last 5 years, Sunshine Biopharma's Beginning Cash Balance surged by 20,863.71% in 2021 and then plummeted by 53.58% in 2023.
  • Quarterly analysis of 5 years shows Sunshine Biopharma's Beginning Cash Balance stood at $2.4 million in 2021, then soared by 1,613.13% to $40.8 million in 2022, then tumbled by 52.73% to $19.3 million in 2023, then plummeted by 39.99% to $11.6 million in 2024, then decreased by 17.94% to $10.1 million in 2025.
  • Its last three reported values are $10.1 million in Q3 2025, $8.5 million for Q2 2025, and $9.7 million during Q1 2025.